Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Chromatin Structure Dynamics Preserve Genome Stability in Multiple Myeloma

Antonis Kokkalis, PhD MSc, Praveen Anand, PhD, Monica S. Nair, Johannes M. Waldschmidt, MD, Julia Frede, PhD MPhil, Tushara Vijaykumar, Amy Guillaumet-Adkins, PhD, Valeriya Dimitrova, Birgit Knoechel, MD PhD, Jens G. Lohr, MD PhD

Blood (2019) 134 (Supplement_1): 1777.

https://doi.org/10.1182/blood-2019-127495

Published: 2019

Journal Articles

Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy

Blood (2019) 134 (Supplement_1): 3091.

https://doi.org/10.1182/blood-2019-130247

Published: 2019

Journal Articles

Determining Resistance Mechanisms in BRAF- mutated Multiple Myeloma

Johannes M. Waldschmidt, MD, Jake A. Kloeber, Tushara Vijaykumar, Antonis Kokkalis, PhD MSc, Praveen Anand, PhD, Sayalee Potdar, Julia Frede, PhD MPhil, Monica S. Nair, Valeriya Dimitrova, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Andrew J. Yee, MD, Noopur S. Raje, MD, Birgit Knoechel, MD PhD, Jens G. Lohr, MD PhD

Blood (2019) 134 (Supplement_1): 316.

https://doi.org/10.1182/blood-2019-130313

Published: 2019

Journal Articles

Enhancer Rewiring Dependent Switch from BCL2 to MCL1 Dependency Predicts NOTCH1 Inhibition Response in T-ALL

Valeriya Dimitrova, Huiyoung Yun, PhD, Sayalee Potdar, Alexandria Nicole Van Scoyk, BS, Shruti Bhatt, PhD, Praveen Anand, PhD, Monica S. Nair, Jake A. Kloeber, Antonis Kokkalis, PhD MSc, Julia Frede, PhD MPhil, Johannes M. Waldschmidt, MD, Anthony G. Letai, MD PhD, David M. Weinstock, MD, Jon C. Aster, MD PhD, Jens G. Lohr, MD PhD, Birgit Knoechel, MD PhD

Blood (2019) 134 (Supplement_1): 3948.

https://doi.org/10.1182/blood-2019-131148

Published: 2019

Journal Articles

Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 4350.

https://doi.org/10.1182/blood-2019-131037

Published: 2019

Journal Articles

Epigenetic Modifications of the Bone Marrow (BM) Niche in Multiple Myeloma (MM) - a Three-Dimensional (3D) in Vitro Approach

Stefan J. Müller, PharmD, Dagmar Wider, Andreas R. Thomsen, MD, Marie Follo, PhD, Johannes M. Waldschmidt, MD, Gabriele Ihorst, Sandra M. Dold, MSc, Julia Felthaus, Johanna Senger, PhD, Julia Schüler, DVM, Justus Duyster, Abdel Kareem Azab, PhD, Martin J. Hug, PhD, Manfred Jung, PhD, Ralph Wäsch, MD, Monika Engelhardt

Blood (2017) 130 (Supplement 1): 1793.

https://doi.org/10.1182/blood.V130.Suppl_1.1793.1793

Published: 2017

Journal Articles

Functional Assessment (FA) in Multiple Myeloma (MM) Patients Predicts Survival: Use of Most Valuable Comorbidity Scores and Functional Tests in a German Study Group (Deutsche Studiengruppe Multiples Myelom [DSMM]) Incentive

Sophia Scheubeck, Gabriele Ihorst, Sandra M. Dold, MSc, Katja Schoeller, Martin Boeker, PD, Stefan J. Müller, PharmD, Johannes M. Waldschmidt, MD, Rebeka Javorniczky, MD, Alessandra Larocca, Margrit Ott, MD, Hermann Einsele, Justus Duyster, Ralph Wäsch, MD, Monika Engelhardt

Blood (2017) 130 (Supplement 1): 3436.

https://doi.org/10.1182/blood.V130.Suppl_1.3436.3436

Published: 2017

Journal Articles

Evaluation of the Risk of Relapse and Survival Using a Conditional Survival Approach in 815 Multiple Myeloma Patients

Maximilian Schinke, Inga Promny, MD, Gabriele Ihorst, PhD, Johannes M. Waldschmidt, MD, Roland H. Mertelsmann, MD PhD, Justus Duyster, MD, Ralph M. Waesch, MD, Martin Schumacher, PhD, Monika Engelhardt, MD

Blood (2016) 128 (22): 5953.

https://doi.org/10.1182/blood.V128.22.5953.5953

Published: 2016

Journal Articles

Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma - Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective Analysis

Giulia Graziani, Gabriele Ihorst, PhD, Johannes M. Waldschmidt, MD, Georg W. Herget, MD PhD, Karl Henne, MD, Annette M. May, Justus Duyster, MD, Werner Vach, PhD, Ralph Wäsch, MD, Monika Engelhardt, MD PhD

Blood (2016) 128 (22): 5979.

https://doi.org/10.1182/blood.V128.22.5979.5979

Published: 2016

Journal Articles

Testing Novel Anti - Multiple Myeloma (MM) Agents in a Suitable Three-Dimensional (3D) Co-Culture Platform

Stefan J. Müller, Dipl.-Pharm., Johannes M. Waldschmidt, MD, Johanna Senger, PhD, Dagmar Wider, Andreas R. Thomsen, MD, Gabriele Ihorst, PhD, Justus Duyster, MD, Martin J. Hug, PhD, Manfred Jung, PhD, Ralph Wäsch, MD, Monika Engelhardt, MD PhD

Blood (2016) 128 (22): 2109.

https://doi.org/10.1182/blood.V128.22.2109.2109

Published: 2016

Journal Articles

PIM1-Mediated CXCR4 Phosphorylation: A Potentially Class-Distinct Therapeutic Target of Next Generation Proteasome Inhibitors in Multiple Myeloma

Johannes M. Waldschmidt, MD, Dagmar Wider, Stefan J. Müller, Dipl.-Pharm., Anna Simon, Sarah Decker, PhD, Marie Follo, PhD, Justus Duyster, MD PhD, Ralph Wäsch, MD, Monika Engelhardt, MD PhD

Blood (2016) 128 (22): 2774.

https://doi.org/10.1182/blood.V128.22.2774.2774

Published: 2016

Journal Articles

Novel Patient Derived Multiple Myeloma Model Reflects Sensitivity Towards Anticancer Treatment in Multiple Myeloma Patients

Julia B. Schueler, DVM, PhD, Dagmar Wider, Kerstin Klingner, Gabrielle Melanie Siegers, PhD, Annette M May, MD, Johannes M. Waldschmidt, MD, Alexander Keller, MD, Justus Duyster, MD, Ralph M. Waesch, MD, Monika Engelhardt, MD

Blood (2015) 126 (23): 3004.

https://doi.org/10.1182/blood.V126.23.3004.3004

Published: 2015

Journal Articles

Results of an Open, Non-Comparative, Phase I/II Investigator Initiated Trial (IIT) in Relapsed or Refractory Multiple Myeloma Patients Using Vorinostat, Bortezomib, Doxorubicin and Dexamethasone (VBDD)

Alexander Keller, MD, Johannes M. Waldschmidt, MD, Dagmar Wider, Dorothee Jakobs, Mandy Möller, Heike Reinhardt, Milena Pantic, PhD, Olga Grishina, MD, Gabriele Ihorst, PhD, Annette M May, MD, Anna Frey, MD, Ulrike Kohlweyer, PhD, Justus Duyster, MD PhD, Manfred Jung, PhD, Monika Engelhardt, MD PhD, Ralph Wäsch, MD PhD

Blood (2015) 126 (23): 4260.

https://doi.org/10.1182/blood.V126.23.4260.4260

Published: 2015

Journal Articles

Mimicking the Myeloma Niche: A 3D Bone-Derived Co-Culture System to Selectively Assess Bystander BMSCs and to Perform High-Throughput Drug Screening in Multiple Myeloma

Johannes M. Waldschmidt, MD, Dagmar Wider, Andreas R. Thomsen, MD, Claudius Klein, Christine Aldrian, Martin Kortuem, MD, Marie Follo, PhD, Julia Schüler, DVM, PhD, Justus Duyster, MD PhD, Monika Engelhardt, MD PhD, Ralph Wäsch, MD PhD

Blood (2015) 126 (23): 1822.

https://doi.org/10.1182/blood.V126.23.1822.1822

Published: 2015

Journal Articles

Conditional Survival Analysis of 816 Multiple Myeloma (MM) Patients Constitutes a Different Way to Provide More Specifically Determined Prognosis

Maximilian Schinke, Inga Promny, MD, Stefanie Hieke, PhD, Johannes M. Waldschmidt, MD, Gabriele Ihorst, PhD, Milena Pantic, PhD, Justus Duyster, MD, Ralph Wäsch, MD PhD, Martin Schuhmacher, PhD, Monika Engelhardt, MD

Blood (2015) 126 (23): 2091.

https://doi.org/10.1182/blood.V126.23.2091.2091

Published: 2015

NARROW

Chromatin Structure Dynamics Preserve Genome Stability in Multiple Myeloma

Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy

Determining Resistance Mechanisms in BRAF- mutated Multiple Myeloma

Enhancer Rewiring Dependent Switch from BCL2 to MCL1 Dependency Predicts NOTCH1 Inhibition Response in T-ALL

Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma

Epigenetic Modifications of the Bone Marrow (BM) Niche in Multiple Myeloma (MM) - a Three-Dimensional (3D) in Vitro Approach

Functional Assessment (FA) in Multiple Myeloma (MM) Patients Predicts Survival: Use of Most Valuable Comorbidity Scores and Functional Tests in a German Study Group (Deutsche Studiengruppe Multiples Myelom [DSMM]) Incentive

Evaluation of the Risk of Relapse and Survival Using a Conditional Survival Approach in 815 Multiple Myeloma Patients

Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma - Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective Analysis

Testing Novel Anti - Multiple Myeloma (MM) Agents in a Suitable Three-Dimensional (3D) Co-Culture Platform

PIM1-Mediated CXCR4 Phosphorylation: A Potentially Class-Distinct Therapeutic Target of Next Generation Proteasome Inhibitors in Multiple Myeloma

Novel Patient Derived Multiple Myeloma Model Reflects Sensitivity Towards Anticancer Treatment in Multiple Myeloma Patients

Results of an Open, Non-Comparative, Phase I/II Investigator Initiated Trial (IIT) in Relapsed or Refractory Multiple Myeloma Patients Using Vorinostat, Bortezomib, Doxorubicin and Dexamethasone (VBDD)

Mimicking the Myeloma Niche: A 3D Bone-Derived Co-Culture System to Selectively Assess Bystander BMSCs and to Perform High-Throughput Drug Screening in Multiple Myeloma

Conditional Survival Analysis of 816 Multiple Myeloma (MM) Patients Constitutes a Different Way to Provide More Specifically Determined Prognosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only